Investigators conducted a randomized, double-blinded, placebo-trolled trial in patients with T2D after an acute coronary syndrome.
CV Risks With Alogliptin in Type 2 Diabetes and Recent Acute Coronary Syndrome posted first on https://www.youtube.com/dailyhealthpost/
No comments:
Post a Comment